Project cooperation
Neo-adjuvant oncolytic immune activator
ORCA-010 is a clinical stage oncolytic with demonstrated safety, clinical effect and ability to induce long term immune activation
CEO
ORCA Therapeutics BV
Amsterdam, Netherlands
Wen Dong (PhD, MBA): CEO at ORCA Therapeutics with 15+ years in oncology drug development from discovery to clinic. Expert in gene therapy, antibodies & CMC.
Skills
Interests
Project cooperation
Neo-adjuvant oncolytic immune activator
ORCA-010 is a clinical stage oncolytic with demonstrated safety, clinical effect and ability to induce long term immune activation
Product
ORCA-010: Enhanced Oncolytic Immunotherapy Platform with 100% Immune Activation Success
ORCA-010 induces 100% long term immune activation in patients, proven safety and efficacy in prostate cancer, and orphan disease potential.